PRODUCTS

TCR-fusion protein therapy

Pipeline

No
Target
Indication
TCR Cloning
Affinity Optimization
Pre-clinical
Clinical Trial
CRPM1A2
Target
MAGE A1
Indication
Multiple tumors
 

IND in 2024

TCR Cloning
 
Optimization
 
Pre-clinical
 
Clinical Trial
 

IND in 2024

CRTKVA11-01 developed for patients with KRAS G12V mutation

The world's first TCR-T therapy for the treatment of advanced solid tumors with KRAS G12V mutation.

  • KRAS is a driver mutation in a variety of tumors

    KRAS is one of the most common mutations in solid tumors, which exists in about 90% of pancreatic cancer, 40% of colorectal cancer and 30% of lung adenocarcinoma.

  • KRAS inhibitors drawbacks

    The vast majority of patients acquired resistance to G12C inhibitors in a short time, and no available candidate drugs for G12D and G12V.

  • KRAS specific TCR-T have showed significant curative effect

    KRAS specific TCR-T have showed significant curative effect in both colorectal cancer and pancreatic cancer.

CRPKVA11
Target
KRAS G12V
Indication
Colorectal &
Pancreatic Cancer
 

IND in 2024

TCR Cloning
 
Optimization
 
Pre-clinical
 
Clinical Trial
 

IND in 2024

CRTKVA11-01 developed for patients with KRAS G12V mutation

The world's first TCR-T therapy for the treatment of advanced solid tumors with KRAS G12V mutation.

  • KRAS is a driver mutation in a variety of tumors

    KRAS is one of the most common mutations in solid tumors, which exists in about 90% of pancreatic cancer, 40% of colorectal cancer and 30% of lung adenocarcinoma.

  • KRAS inhibitors drawbacks

    The vast majority of patients acquired resistance to G12C inhibitors in a short time, and no available candidate drugs for G12D and G12V.

  • KRAS specific TCR-T have showed significant curative effect

    KRAS specific TCR-T have showed significant curative effect in both colorectal cancer and pancreatic cancer.

CRPKDA11
Target
KRAS G12D
Indication
Colorectal &
Pancreatic Cancer
 

 

TCR Cloning
 
Optimization
 
Pre-clinical
 
Clinical Trial
 

CRTKVA11-01 developed for patients with KRAS G12V mutation

The world's first TCR-T therapy for the treatment of advanced solid tumors with KRAS G12V mutation.

  • KRAS is a driver mutation in a variety of tumors

    KRAS is one of the most common mutations in solid tumors, which exists in about 90% of pancreatic cancer, 40% of colorectal cancer and 30% of lung adenocarcinoma.

  • KRAS inhibitors drawbacks

    The vast majority of patients acquired resistance to G12C inhibitors in a short time, and no available candidate drugs for G12D and G12V.

  • KRAS specific TCR-T have showed significant curative effect

    KRAS specific TCR-T have showed significant curative effect in both colorectal cancer and pancreatic cancer.

CRPE7A2
Target
HPV16 E7
Indication
HPV16 infection,
Cervical cancer
 

 

TCR Cloning
 
Optimization
 
Pre-clinical
 
Clinical Trial
 

CRTKVA11-01 developed for patients with KRAS G12V mutation

The world's first TCR-T therapy for the treatment of advanced solid tumors with KRAS G12V mutation.

  • KRAS is a driver mutation in a variety of tumors

    KRAS is one of the most common mutations in solid tumors, which exists in about 90% of pancreatic cancer, 40% of colorectal cancer and 30% of lung adenocarcinoma.

  • KRAS inhibitors drawbacks

    The vast majority of patients acquired resistance to G12C inhibitors in a short time, and no available candidate drugs for G12D and G12V.

  • KRAS specific TCR-T have showed significant curative effect

    KRAS specific TCR-T have showed significant curative effect in both colorectal cancer and pancreatic cancer.

 
Target
HBV Env
Indication
Hepatitis B
 

 

TCR Cloning
 
Optimization
 
Pre-clinical
 
Clinical Trial
 

CRTKVA11-01 developed for patients with KRAS G12V mutation

The world's first TCR-T therapy for the treatment of advanced solid tumors with KRAS G12V mutation.

  • KRAS is a driver mutation in a variety of tumors

    KRAS is one of the most common mutations in solid tumors, which exists in about 90% of pancreatic cancer, 40% of colorectal cancer and 30% of lung adenocarcinoma.

  • KRAS inhibitors drawbacks

    The vast majority of patients acquired resistance to G12C inhibitors in a short time, and no available candidate drugs for G12D and G12V.

  • KRAS specific TCR-T have showed significant curative effect

    KRAS specific TCR-T have showed significant curative effect in both colorectal cancer and pancreatic cancer.

Tumor indications covered by our early TCR-T products

Antigen targets
under development
Covered HLA genotypes
China Han
Caucasian
Covered HLA genotypes
China Han
Caucasian

Infectious diseases covered by our TCR-fusion protein therapies

Chronic HPV infection

About 300million patients worldwide, tens of millions of patien

There is no effective treatment

HPV specific TCR-fusion protein therapy is expected to eliminate HPV infected cells and cure HPV infection

Chronic HBV infection

About 260million patients worldwide and 70 million patients in China

Available treatment can only inhibit virus replication, but can't eliminate the virus

HBV specific TCR-fusion protein therapy is expected to eliminate infection

Product advantages

TCR-fusion protein
  • More targets than antibody
  • Controlled PK and Safty
  • Off-the-shelf products
  • Opportunity for larger patient reach & favorable commercial